Erdheim-Chester Disease

15 clinical trials · Condition

Record	Firm	Date
The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation (NCT05092815)	Shanghai Henlius Biotech	2021-12-06
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET (NCT05093335)	Memorial Sloan Kettering Cancer Center	2021-10-01
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NCT04079179)	Carl Allen	2021-04-19
Subtypes and Prognostic Factors in Erdheim-Chester Disease (NCT06317246)	Meyer Children's Hospital IRCCS	2020-09-15
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (NCT04198818)	Haihe Biopharma Co., Ltd.	2020-01-07
GWAS and EWAS in Patients With Erdheim-Chester Disease (NCT06332183)	Augusto Vaglio	2019-07-17
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations (NCT03794297)	National Cancer Institute (NCI)	2019-01-04
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses (NCT03329274)	Memorial Sloan Kettering Cancer Center	2017-10-26
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement (NCT02608619)	Memorial Sloan Kettering Cancer Center	2015-11-01
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease (NCT02089724)	Groupe Hospitalier Pitie-Salpetriere	2014-03-01
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease (NCT01727206)	Ospedale San Raffaele	2012-11-01
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434)	M.D. Anderson Cancer Center	2012-10-16

Track Erdheim-Chester Disease automatically

Every clearance here is in the API, with alerts when new ones post.